Special Issue "Therapy in Rheumatoid Arthritis: Current Evidence and Future Directions"
A special issue of Medicina (ISSN 1648-9144).
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 5102
Interests: immune-mediated inflammatory rheumatic disorders; rheumatoid arthritis, spondyloarthritis; connective tissue diseases – systemic sclerosis, systemic lupus erythematosus, poli/dermatomyositis; biological therapies
Special Issues, Collections and Topics in MDPI journals
Rheumatoid arthritis (RA) represents a chronic immune-mediated inflammatory disease characterized by progressive and irreversible tissue destruction, functional disability, and altered quality of life; it is a complex and dynamic condition, extremely heterogeneous, especially from clinical, serological, and therapeutic outlooks.
Choosing a realistic target, depending on the clinical scenario and prognostic factors, has become the actual standard of care in RA, with remission or low-activity disease being the major therapeutic goals. Furthermore, the multistep therapeutic algorithm of the disease clearly emphasizes the true significance of earlier (in the so-called “window of opportunity”), aggressive, dynamic, as well as individualized RA treatment, frequently adapted to disease activity and therapeutic response.
Over time, TNF and non-TNF biologics and targeted synthetic small molecules (JAK inhibitors) have expanded our knowledge and radically changed the outcomes of AR; regardless of their mechanism of action and irrespective of the clinical and therapeutic scenario (early vs. advanced RA, naïve vs. experienced patients, difficult-to-treat disease, refractory to multiple therapeutic options), biologics and JAKinibs have demonstrated comparable efficacy, without any preference or hierarchy in administration. Therefore, the choice of optimal medication remains a challenge in daily practice, for reasons of safety and comorbidities.
The purpose of this Special Issue is to explore and debate a range of issues around personalized RA management taking into account different RA settings. This is an opportunity for both physicians and researchers at the forefront of the evolving RA therapeutic landscape to contribute to this exciting field, looking beyond remission and into the future of RA management.
Prof. Dr. Codrina Ancuta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- rheumatoid arthritis
- TNF inhibitors
- non-TNF inhibitors
- targeted synthetic DMARDs
- JAK inhibitors
- conventional synthetic DMARDs